Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 6/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668336 | 0.96 | AGTR1 (0.57) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL668511 | 0.92 | AGTR1 (0.51) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL667461 | 0.92 | AGTR1 (0.53) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7885241 | 0.91 | AGTR1 (0.49) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7885252 | 0.91 | AGTR1 (0.49) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL683727 | 0.91 | AGTR1 (0.58) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL12991421 | 0.90 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL986792 | 0.90 | AGTR1 (0.62) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL668491 | 0.90 | AGTR1 (0.51) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL3842922 | 0.89 | AGTR2 (0.55) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | claimed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | claimed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | claimed |
| EP-1884240-B1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | DAIICHI SANKYO CO LTD (JP) | 2009-11-11 | — | — | EP | claimed |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | DAIICHI SANKYO COMPANY, LIMITED (75% INTEREST) (JP) | 2009-03-26 | — | — | US | claimed |
| EP-1884240-A1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | Daiichi Sankyo Company, Limited (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120046327-A1 | METHOD FOR INHIBITING THE INDUCTION AND FORMATION OF OSTEOCLASTS | OSAKA UNIVERSITY (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
| EP-1884240-B1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | DAIICHI SANKYO CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | DAIICHI SANKYO COMPANY, LIMITED (75% INTEREST) (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1884240-A1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | Daiichi Sankyo Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | AGTR1, AGTR2, ACE | AGTR1 1/4885AGTR2 2/4885ABCC3 1034/4885 |
| US-20120046327-A1 | METHOD FOR INHIBITING THE INDUCTION AND FORMATION OF OSTEOCLASTS | SOST, CD14, MYD88 | AGTR1 35/4885AGTR2 64/4885ABCC3 4200/4885 |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885ABCC3 1984/4885 |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | AGTR1, AGTR2, MC2R | AGTR1 1/4885AGTR2 2/4885ABCC3 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.